doc. MUDr. Radka Lordick Obermannová, Ph.D.
Associate professor, Comprehensive Cancer Care Department
Total number of publications: 65
2025
-
Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypND and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study
Annals of Oncology, year: 2025, volume: 36, edition: 2, DOI
-
ESMO Clinical Practice Guideline interim update on the treatment of locally advanced oesophageal and oesophagogastric junction adenocarcinoma and metastatic squamous-cell carcinoma
ESMO OPEN, year: 2025, volume: 10, edition: 2, DOI
-
How do I treat dMMR/MSI gastro-oesophageal adenocarcinoma in 2025? A position paper from the EORTC-GITCG gastro-esophageal task force
CANCER TREATMENT REVIEWS, year: 2025, volume: 134, edition: March 2025, DOI
-
Optimal timing for initiating first-line palliative systemic therapy in asymptomatic metastatic esophagogastric cancer: Insights from a European Delphi study
European Journal of Cancer, year: 2025, volume: 218, edition: March 2025, DOI
2024
-
7. setkání CZECRIN ONCO
Year: 2024, type: Workshop
-
8. setkání CZECRIN ONCO
Year: 2024, type: Workshop
-
European clinical practice guidelines for the definition, diagnosis, and treatment of oligometastatic esophagogastric cancer (OMEC-4)
European Journal of Cancer, year: 2024, volume: 204, edition: June 2024, DOI
-
Perioperační systémová léčba jako součást komplexní multimodální terapie u nádorů jícnu a žaludku – současné standardy a nadějné novinky
Rozhledy v Chirurgii, year: 2024, volume: 103, edition: 11, DOI
-
Problematika péče o mladé dospělé onkologické pacienty v Česku: Je třeba národních doporučených postupů?
Časopis lékařů českých, year: 2024, volume: 2024, edition: 7-8
-
RAS mutation specific survival in patients with metastatic colorectal cancer treated with trifluridine/tipiracil.
Year: 2024, type: Conference abstract